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We are encountering a significant progress in nutritional knowledge, relevant to the practice of
all aspects of human nutrition, medicine and public health. So, it is conceivable that we may
view the role of nutrition differently in the future. The diet may not only provide an adequate
amount of nutrients to meet the metabolic requirements, but could also contribute to improving
human health status. As a consequence, extracts of plants or single compounds thereof which are
believed to benefit human health need to be identified and developed for the food market to
complement a balanced diet. The assessment of risk and benefit of constituents of a diet or
plants will be a challenge for scientists working in this area. The number of compounds to be
tested is enormous. Their impact on human health is supposed to be through prevention. Their
effect on the human system may be modest, yet still significant when consumed over an entire
lifespan. Trials employing traditional clinical endpoints, for many reasons, appear not to be
feasible to investigate the relevance of these compounds on human health. Rather biomarkers,
which are ‘surrogate endpoints’ for clinical events, may be used in the field of nutritional
science. These biomarkers have to be highly sensitive and specific, non- or minimally invasive
and inexpensive and they need to be validated and standardized. The biomarker concept may
prove essential in nutritional science to demonstrate the effect of diet constituents on human
health.
Biomakers: Nutritional science: Industry
Background
Demographics are changing dramatically in different
countries all over the globe. In particular, in the Western
World the population is ageing rapidly. In the United States
(US) for example, the number of people aged 65 years and
over is expected to double in the next decades. Americans
older than 45 years will constitute almost one-half of the
population (Hasler, 1996). These demographic changes will
have important implications on both, the incidence of
chronic diseases and health-care costs. On the other hand,
we are encountering significant progress in nutritional
knowledge, relevant to the practice of all aspects of human
nutrition, medicine and public health. So, it is conceivable
that we may view the role of nutrition differently in the
future. Consumer expectations and demands of a diet may
also change. In fact, there is evidence (Heasman, 1998) that
the consumer may favour a diet, which not only provides an
adequate amount of nutrients to meet the metabolic
requirements, but can also contribute to improve human
health status.
Actually, this process started some time ago. In the
1970s, scientists began to consider a diet high in fat and
cholesterol as a risk factor for cardiovascular diseases.
Subsequently, as appropriate foods became available in
the marketplace people started to prefer low fat and
cholesterol-free foods over conventional food, so as to
minimize their cardiovascular risk. However, it appears that
‘taking out bad things’ (e.g. fat, sugar, etc.) from the diet is
no longer good enough. To complement a balanced diet,
scientists are now suggesting ‘putting back or even
enhancing the good things’ (vitamins, polyunsaturated
fatty acids, etc.) in the diet. As a consequence, extracts of
plants or single compounds thereof, which are believed to
benefit human health, need to be identified and developed
for the food market.
The challenge
To make this happen appears to be quite a challenge for
scientists in academia, in regulatory agencies and in
industry. This comment is about the possible role and
value of the biomarker concept in terms of nutritional
science being carried out in industry.
Clearly, most of the extracts or single compounds of
plants perceived to be healthy are basically non-
essential and many do not have, what in the US is
being referred to as a ‘generally regarded as safe’
(GRAS) status. So, first of all it has to be shown that
these compounds are safe. Secondly, the putative health
effect on the human body of a given compound has to
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be demonstrated by sound scientific experiments.
Demonstration of efficacy is important to the industry,
so a claim could then be made on a particular compound or
product.
The assessment of risk and benefit of constituents of a
diet or plants will be a challenge for scientists working in
this area. The number of compounds to be tested is
enormous. Furthermore, and even more importantly, the
impact of a diet or single constituent on the human system
may be modest at the time, yet may be significant when
consumed over the entire lifespan. Plus, if these ‘healthy’
constituents are targetted against chronic diseases such as
cardiovascular diseases or osteoporosis, there is another
issue. Many chronic diseases may take a long time period
to develop clinically overt symptoms (Hansson et al.
1994). For example, atherosclerotic alterations may be
seen in situ in young adults or even earlier (Stary, 1987),
yet clinical symptoms typically become evident only in
later life. Also, for malignancies such as stomach cancer
or prostate cancer it is known that from initiation of an
aberrant cell to clinically overt cancer it may take 20 or
more years. So, the inherent conflict of nutritional science
is to demonstrate a significant effect of a given compound
in a short amount of time, which very often will not
resemble reality.
Scientific tools
The different categories of scientific evidence used to
pinpoint an effect of a certain compound are in vitro tests
(molecular/cellular assays), animal experiments, epidemio-
logical studies and clinical trials. The definitive proof of a
certain hypothesis, as generated in epidemiological studies,
and further substantiated through in vitro assays and in
animal experiments, eventually requires human clinical
trials. The proof of efficacy in clinical trials, however, for
the above reasons is problematic in nutritional sciences,
when traditional clinical endpoints (i.e. myocardial
infarction cancer incidence, fracture rate etc.) are being
employed.
Biomarker concept and nutritional science
The biomarkers or ‘surrogate endpoints’ could be an
opportunity to avoid that dilemma, when used instead of
clinical endpoints in the field of nutritional science (Zeger,
1999), Table 1 lists the definition of biomarkers, clinical
endpoints and surrogate endpoints as defined by Zeger
(1999). These biomarkers have of course to meet some
criteria to be useful. They have to be (1) highly sensitive
and specific, (2) non- or minimally invasive, (3) validated
and standardized, and (4) inexpensive. The biomarker
concept may become an essential element in nutritional
science to demonstrate the modest effect of nutrients or
plant constituents on the human body within a reasonable
period time and at reasonable costs. This applies, in
particular to the development of compounds, which are
intended to be used in food, so as to improve human health.
Some examples of biomarkers relevant to nutritional
science are given in Table 2. However, it must be realized
that there are limitations to the biomarker concept. There
will be no single biomarker which is ideal. The appropriate
use of biomarkers may require a set of biomarkers aiming
at the same indication. The result of these different
biomarkers will generate a pattern, which will then be
useful to assess the effect of a given compound on a certain
condition or chronic disease. Not only will the result of the
different markers always be unequivocal but also the
different categories of scientific evidence such as epide-
miology, molecular and cellular assays, animal experiments
and eventually human trials will lead to results which have
a different degree of scientific soundness. This may result
in a grading of the scientific evidence that will be obtained
from different studies. Scientifically solid results from
clinical trials may be used to make a ‘hard’ claim, whereas
associative data together with a set of preclinical data may
only classify for a ‘soft’ claim (Fig. 1).
Table 1. Definition of biomarkers, clinical endpoints and surrogate
endpoints
• Biomarker
A characteristic that is measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or
pharmacologic responses to an intervention
• Clinical endpoint
Variable that measures how a patient feels, functions or
survives
• Surrogate endpoint
A biomarker intended to substitute for a clinical endpoint
From Zeger (1999).
Table 2. Examples of biomarkers and clinical endpoints
• Cardiovascular diseases
Biomarkers: serum cholesterol levels, blood pressure
Clinical endpoint: myocardial infarction, stroke
• Osteoporosis
Biomarkers: markers of bone remodelling
(formation/resorption), bone mineral density
Clinical endpoint: hip (spine) fractures
• Cancer, i.e. prostate
Biomarker: Prostate specific antigen
Clinical endpoint: neoplasm in the prostate or metastasis
Fig. 1. Scientific evidence and claims.
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Also, the biomarker concept can be applied to test the
safety of compounds. Traditionally, safety testing is carried
out with animals and a set of clinical chemistry parameters
is being assayed to assess the safety of that particular
compound. The use of specific and sensitive molecular
markers of organ damage, cellular and molecular signals as
surrogates for tissue damage and eventually appropriate
transgenic animal models may help to minimize animal
testing. Finally, (molecular) biomarker approaches are
useful while screening and identifying compounds which
may potentially benefit human health.
Conclusions
The biomarker concept could facilitate a number of
opportunities in academia, in regulatory authorities and in
industry. For academia this concept could present a great
research area to accelerate knowledge in nutritional
science. A prerequisite to that is the validation of
biomarkers. Clearly, collaboration between academia,
regulatory authorities and industry is required, if this
concept is to be successful. The interaction between
academia, regulatory authorities and industry should be
dynamic, in that knowledge will be applied as it becomes
available and be replaced as there is superior information.
From the industry perspective the biomarker concept could
help to accelerate identification and testing of compounds,
to develop a mechanism-based safety and efficacy concept
of food constituents and to establish test models suitable for
nutritional science. One of the key issues will be to
translate biomarker-based scientific evidence into claims,
which are required to successfully market a particular
product.
In general, the biomarker concept may prove to be a
fundamentally important element in research related to
nutrition and public health. This may be a critical issue in
the future as the demographics are expected to change
dramatically within the next decade, so traditional public
health services may face significant limitations.
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